Pharma BD Deal Intelligence
The transaction provides Endo with a strong growth platform in Mexico that we believe can be further leveraged more broadly in Latin America... Somar's robust…
Endo to buy Mexican specialty pharma Somar for cash, extending its branded footprint into Latin America via $100M-revenue platform with 1,200 employees and…
Endo agreed to divest Grupo Farmaceutico SOMAR to Advent International for ~$124M, exiting Mexico as part of CEO Paul Campanelli's retrenchment to core US…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Endo agreed to acquire privately held Mexico City-based specialty pharma Somar for cash, with reported value of approximately US$270M. The deal extended Endo's international branded footprint into Latin America, with 60+ products in the launch pipeline. Closed July 24, 2014.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo International plc / Grupo Farmaceutico Somar SAPI de CV (this deal) | 2014 | $270M | 18 |
| Endo International plc / Auxilium Pharmaceuticals, Inc. | 2014 | $2.6B | 47 |
| Endo International plc / DAVA Pharmaceuticals, Inc. | 2014 | $600M | 25 |
| Endo International plc / Par Pharmaceutical Holdings, Inc. | 2015 | $8.1B | 15 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2014 deals · Endo International plc deals · Other deals